Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Earns "Buy" Rating from D. Boral Capital

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX - Get Free Report)'s stock had its "buy" rating reissued by equities researchers at D. Boral Capital in a research report issued to clients and investors on Monday,Benzinga reports. They currently have a $2.00 target price on the stock. D. Boral Capital's price target would indicate a potential upside of 107.40% from the stock's previous close.

LCTX has been the subject of a number of other research reports. HC Wainwright restated a "buy" rating and issued a $9.00 price objective on shares of Lineage Cell Therapeutics in a research report on Monday. B. Riley lowered their price target on Lineage Cell Therapeutics from $4.00 to $3.00 and set a "buy" rating for the company in a report on Friday, March 14th. Five analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of "Buy" and an average target price of $4.20.

Lineage Cell Therapeutics Stock Down 9.9%

Lineage Cell Therapeutics stock traded down $0.11 during midday trading on Monday, hitting $0.96. 3,017,833 shares of the stock were exchanged, compared to its average volume of 1,469,615. The stock has a market capitalization of $220.21 million, a PE ratio of -12.05 and a beta of 1.52. The company has a fifty day simple moving average of $0.62 and a two-hundred day simple moving average of $0.62. Lineage Cell Therapeutics has a 52 week low of $0.37 and a 52 week high of $1.15.

Institutional Trading of Lineage Cell Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of LCTX. Fort Sheridan Advisors LLC lifted its position in shares of Lineage Cell Therapeutics by 71.5% in the fourth quarter. Fort Sheridan Advisors LLC now owns 55,177 shares of the company's stock worth $28,000 after purchasing an additional 23,000 shares in the last quarter. HighTower Advisors LLC increased its stake in Lineage Cell Therapeutics by 49.5% in the 4th quarter. HighTower Advisors LLC now owns 57,706 shares of the company's stock valued at $29,000 after buying an additional 19,100 shares during the last quarter. Atria Wealth Solutions Inc. bought a new stake in Lineage Cell Therapeutics during the 4th quarter worth about $29,000. Two Sigma Advisers LP boosted its stake in shares of Lineage Cell Therapeutics by 312.2% during the 4th quarter. Two Sigma Advisers LP now owns 86,964 shares of the company's stock worth $44,000 after buying an additional 65,864 shares during the last quarter. Finally, Squarepoint Ops LLC bought a new position in shares of Lineage Cell Therapeutics in the 4th quarter valued at about $46,000. Institutional investors and hedge funds own 62.47% of the company's stock.

Lineage Cell Therapeutics Company Profile

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.